Navigation Links
Pittcon Announces Exhibiting Schedule for Remainder of 2013
Date:8/15/2013

lists and editors are cordially invited to stop by the Pittcon 2014 booth at any of the above referenced events to get the latest information regarding our conference and exposition.

About Pittcon

Pittcon® is a registered trademark of The Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, a Pennsylvania non-profit organization. Co-sponsored by the Spectroscopy Society of Pittsburgh and the Society for Analytical Chemists of Pittsburgh, Pittcon is the premier annual conference and exposition on laboratory science. Proceeds from Pittcon fund science education and outreach at all levels, kindergarten through adult. Pittcon donates more than a million dollars a year to provide financial and administrative support for various science outreach activities including science equipment grants, research grants, scholarships and internships for students, awards to teachers and professors, and grants to public science centers, libraries and museums. Visit pittcon.org for more information.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11022207.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Pittcon 2013 Launches New Website
2. Pittcon 2013 Announces Call for Topics for Conferee Networking Sessions, August 1, 2012 Deadline
3. Pittcon Announces 2013 Award Recipients; New Award, Robert Boyle Prize for Analytical Science, Added to Technical Program
4. Chemical Imaging Spectroscopy is the Focus for Pittcon 2013 Waters Symposium
5. Pittcon and Food Safety Tech Announce Strategic Conference Partnership
6. Secretary of Department of Environmental Protection, Michael Krancer, to Facilitate Networking Session at Pittcon 2013
7. FDA to Discuss Food Safety Modernization Act (FSMA) at Food Labs Conference in Conjunction with Pittcon 2013
8. Cole-Parmer Features New Masterflex and Laboratory Technologies at Pittcon 2013
9. Pittcon Announces the 2013 Pittsburgh Conference Memorial National College Grant Awardees
10. PolyScience to Exhibit Its Latest Liquid Temperature Control Solutions at Pittcon 2013
11. Pittcon 2013 Announces Exposition Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a commercial focus on China , ... (CFDA) has approved the Company,s application to conduct a ... carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an ... and monetization of intellectual property, today provided an ... and  Spherix v. Uniden , Case No. 3:13-cv-03496-M, ... the Northern District of Texas ... Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the United ...
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... 2015  Caris Life Sciences® today announced the ... Intelligence®, the company,s panomic, comprehensive tumor profiling service, ... rare and difficult to treat gynecological cancers may ... to improve patient outcomes. These studies were presented ... of Gynecologic Oncology (SGO) 2015 Annual Meeting on ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4
... VILLAGE, Nev., June 8 PDL BioPharma, Inc. (PDL) (Nasdaq: ... second quarter ended June 30, 2009 of approximately $125 million, ... 2008. The increase is due primarily to royalty revenues driven ... marketed by Genentech, and sales of Tysabri(R), which is marketed ...
... reductions in fasting plasma glucose, HbA1c and body weight ... 8 Intarcia Therapeutics, Inc. today presented results from ... delivery of exenatide) for the treatment of type 2 ... the American Diabetes Association in New Orleans, LA (June ...
... N.J., June 8 Celator Pharmaceuticals today announced ... extended therapeutic bioavailability and tumor cell selectivity of ... at the 14th Congress of the European Hematology ... (Abstracts 1398 and 383). , , "These ...
Cached Biology Technology:PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million 2PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million 3Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 3Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 4Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 2Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 3
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
(Date:3/12/2015)... March 12, 2015 The mascots of the ... Hospital, part of Wake Forest Baptist Medical Center. They ... the 2015 ACC Men,s Basketball Tournament. Young patients enjoyed ... and getting their autographs. Brenner Children,s Hospital ... is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... 2010 UT Southwestern Medical Center researchers have found new ... susceptible to stress than others. In a study of ... event, animals that were more susceptible to stress exhibited enhanced ... brain. Specifically, the cells that these animals produced after a ...
... Hemophilia, a disease linked with legends of European monarchs, frail ... people today. And the very treatments that can help ... treatment is infusion with an expensively produced protein that helps ... system fights the therapy, and in a subset of those, ...
... N.J. ―The Center for Secure and Resilient Maritime Commerce (CSR) ... report. Stevens was named by the US Department ... Centers of Excellence and was selected to lead a national ... 11 universities to partner with the DHS and serve as ...
Cached Biology News:New brain nerve cells key to stress resilience, UT Southwestern researchers find 2New brain nerve cells key to stress resilience, UT Southwestern researchers find 3Researchers harness the power of plants to fight hemophilia 2Researchers harness the power of plants to fight hemophilia 3Researchers harness the power of plants to fight hemophilia 4
5 minutes from gel band to purified DNA...
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
DTT, 25g...
AgarPlaque Plus Agarose 50 grams...
Biology Products: